TuHURA Biosciences
TAMPA, FL · Biotechnology, Health Care, Therapeutics · 23 employees
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.
Funding history
- Funding Round — $50.0M — Apr 2026
- Funding Round — $12.5M — Jun 2025
- Series seed — $1.7M — Dec 2023
- Funding Round — $5.1M — Nov 2021
- Series seed — $2.7M — Dec 2020
Recent signals
- Apr 22, 2026: Raised $50.0M
- Mar 23, 2026: TuHURA Biosciences Appoints Dr. Craig L. Tendler as Chief Medical Officer
- Jun 03, 2025: Raised $12.5M
- Apr 07, 2025: TuHURA Appoints Bertrand Le Bourdonnec as Executive Vice President
- Jul 08, 2024: TuHURA Biosciences Enters Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
- Dec 27, 2023: Raised $1.7M in Series seed
- Nov 19, 2021: Raised $5.1M
- Dec 17, 2020: Raised $2.7M in Series seed
See plans & pricing → Track TuHURA Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.